High Rate of Drug‐Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis

Authors:
Publisher website
Google Scholar
Abstract
Objective: New treatment algorithms using tumor necrosis factor (TNF) blockers in early stages of spondyloarthritis (SpA) induce high rates of clinical remission or low disease activity. It could be anticipated that such early intervention strategies in peripheral SpA may induce drug‐free remission. We undertook this study to evaluate drug‐free clinical remission after induction therapy with golimumab in patients with very early active peripheral SpA, and to identify patient characteristics that predict sustained drug‐free remission.Methods: Eligible patients were age ≥18 years and fulfilled the Assessment of SpondyloArthritis international Society criteria for peripheral SpA. All patients had symptom duration of 5).Conclusion: Anti‐TNF treatment in very early peripheral SpA results in a remarkably high rate of sustained clinical remission. More than 50% of patients continue to have remission of their disease after withdrawal of therapy, which highlights a defined window of opportunity permitting induction of drug‐free remission.
Funding Information
  • Janssen Pharmaceutica

This publication has 31 references indexed in Scilit: